D.A. Davidson & CO. trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 6.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,814 shares of the medical research company’s stock after selling 3,001 shares during the period. D.A. Davidson & CO.’s holdings in Edwards Lifesciences were worth $3,417,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. Edmond DE Rothschild Holding S.A. lifted its holdings in Edwards Lifesciences by 11.9% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 22,126 shares of the medical research company’s stock valued at $1,651,000 after acquiring an additional 2,353 shares during the period. Stonegate Investment Group LLC lifted its holdings in Edwards Lifesciences by 22.3% in the 1st quarter. Stonegate Investment Group LLC now owns 13,118 shares of the medical research company’s stock worth $1,085,000 after purchasing an additional 2,392 shares in the last quarter. Vontobel Holding Ltd. grew its stake in Edwards Lifesciences by 72.6% during the first quarter. Vontobel Holding Ltd. now owns 729,156 shares of the medical research company’s stock valued at $60,323,000 after acquiring an additional 306,664 shares in the last quarter. Plimoth Trust Co. LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $316,000. Finally, Verus Capital Partners LLC raised its stake in Edwards Lifesciences by 220.0% during the third quarter. Verus Capital Partners LLC now owns 4,330 shares of the medical research company’s stock valued at $358,000 after purchasing an additional 2,977 shares in the last quarter. 79.78% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
EW has been the topic of a number of recent analyst reports. Barclays increased their target price on Edwards Lifesciences from $94.00 to $102.00 in a research note on Friday, April 28th. 1-800-FLOWERS.COM restated a “reiterates” rating on shares of Edwards Lifesciences in a report on Tuesday, June 27th. TheStreet upgraded shares of Edwards Lifesciences from a “c+” rating to a “b-” rating in a report on Wednesday, April 19th. 92 Resources reissued a “reiterates” rating on shares of Edwards Lifesciences in a report on Thursday, May 4th. Finally, Piper Sandler upped their price objective on Edwards Lifesciences from $80.00 to $83.00 in a research note on Thursday, April 27th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $90.68.
Edwards Lifesciences Trading Up 1.5 %
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings data on Wednesday, April 26th. The medical research company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. Edwards Lifesciences had a return on equity of 25.81% and a net margin of 27.07%. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.39 billion. During the same period in the prior year, the firm posted $0.60 EPS. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. Analysts anticipate that Edwards Lifesciences Co. will post 2.55 earnings per share for the current year.
Insider Buying and Selling at Edwards Lifesciences
In other news, CEO Michael A. Mussallem sold 19,875 shares of the firm’s stock in a transaction on Friday, April 14th. The shares were sold at an average price of $84.20, for a total value of $1,673,475.00. Following the transaction, the chief executive officer now owns 60,948 shares of the company’s stock, valued at approximately $5,131,821.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Michael A. Mussallem sold 19,875 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, April 14th. The stock was sold at an average price of $84.20, for a total value of $1,673,475.00. Following the completion of the transaction, the chief executive officer now owns 60,948 shares in the company, valued at approximately $5,131,821.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,635 shares of Edwards Lifesciences stock in a transaction dated Friday, May 5th. The shares were sold at an average price of $88.62, for a total transaction of $499,373.70. Following the completion of the transaction, the vice president now directly owns 56,225 shares of the company’s stock, valued at $4,982,659.50. The disclosure for this sale can be found here. Insiders have sold a total of 236,031 shares of company stock valued at $20,758,702 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- 3 Stocks that Analysts Continue to Upgrade into Earnings Season
- Meta Threads Its Way To New HeightsÂ
- Helen of Troy and NanoString Technologies Trade Set-ups
- Profit Taking Hits Home for Specialty Retailers
- The 3 Hot Sectors To Watch During The Summer Reporting Season
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
